Stanley Fahn

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. pmc Neurodegeneration and neuroprotection in Parkinson disease
    Stanley Fahn
    Department of Neurology, Columbia University, New York, New York 10032, USA
    NeuroRx 1:139-54. 2004
  2. ncbi Levodopa and the progression of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    N Engl J Med 351:2498-508. 2004
  3. ncbi Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Stanley Fahn
    Neurological Institute, Columbia University College of Physicians and Surgeons, 710 West 168th Street, New York, NY 10032, USA
    J Neurol 252:IV37-IV42. 2005
  4. doi The history of dopamine and levodopa in the treatment of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    Mov Disord 23:S497-508. 2008
  5. doi How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?
    Stanley Fahn
    Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Ann Neurol 64:S56-64. 2008
  6. ncbi Description of Parkinson's disease as a clinical syndrome
    Stanley Fahn
    Department of Neurology, Columbia University College of Physicians Surgeons, New York, New York 10032, USA
    Ann N Y Acad Sci 991:1-14. 2003
  7. pmc Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method
    Yuanjia Wang
    Department of Biostatistics, Mailman School of Public Health, New York, New York, USA
    Arch Neurol 65:467-74. 2008
  8. pmc Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study
    Elise Caccappolo
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    J Int Neuropsychol Soc 17:91-100. 2011
  9. pmc Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study
    Karen S Marder
    Taub Institute for Research on Alzheimer s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, 630 W 168th St, Unit 16, New York, NY 10032, USA
    Arch Neurol 67:731-8. 2010
  10. pmc Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease
    Roy N Alcalay
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Clin Exp Neuropsychol 32:775-9. 2010

Detail Information

Publications68

  1. pmc Neurodegeneration and neuroprotection in Parkinson disease
    Stanley Fahn
    Department of Neurology, Columbia University, New York, New York 10032, USA
    NeuroRx 1:139-54. 2004
    ..We then outline potential approaches to neuroprotection for PD that are derived from current notions on disease pathogenesis...
  2. ncbi Levodopa and the progression of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    N Engl J Med 351:2498-508. 2004
    ..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease...
  3. ncbi Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Stanley Fahn
    Neurological Institute, Columbia University College of Physicians and Surgeons, 710 West 168th Street, New York, NY 10032, USA
    J Neurol 252:IV37-IV42. 2005
    ..Levodopa's toxicity to neurons in vitro has raised concerns if it might hasten the progression of PD, although in vivo animal studies suggest it may be neuroprotective...
  4. doi The history of dopamine and levodopa in the treatment of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    Mov Disord 23:S497-508. 2008
    ..Their impact went beyond a single clinical entity of parkinsonism, for it opened up the beginning of a much better understanding of the role of dopamine in other neurologic movement disorders and also in many psychiatric diseases...
  5. doi How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?
    Stanley Fahn
    Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Ann Neurol 64:S56-64. 2008
    ..There is thus a need for experienced and knowledgeable physicians and surgeons who are able to handle these motor complications. This review discusses available medications and surgical approaches, and their outcomes...
  6. ncbi Description of Parkinson's disease as a clinical syndrome
    Stanley Fahn
    Department of Neurology, Columbia University College of Physicians Surgeons, New York, New York 10032, USA
    Ann N Y Acad Sci 991:1-14. 2003
    ..Nonmotor symptoms (depression, lack of motivation, passivity, and dementia) are common. As the disease progresses, even motor symptoms become intractable to therapy. No proven means of slowing progression have yet been found...
  7. pmc Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method
    Yuanjia Wang
    Department of Biostatistics, Mailman School of Public Health, New York, New York, USA
    Arch Neurol 65:467-74. 2008
    ..To estimate the risk of Parkinson disease (PD) in individuals with mutations in the Parkin gene...
  8. pmc Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study
    Elise Caccappolo
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    J Int Neuropsychol Soc 17:91-100. 2011
    ..Carriers of parkin mutations, whether or not they have PD, do not perform differently on neuropsychological measures as compared to noncarriers. The cognitive functioning of parkin carriers over time warrants further study...
  9. pmc Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study
    Karen S Marder
    Taub Institute for Research on Alzheimer s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, 630 W 168th St, Unit 16, New York, NY 10032, USA
    Arch Neurol 67:731-8. 2010
    ..Mutations in the parkin gene are the most common genetic cause of early-onset Parkinson disease (PD). Results from a multicenter study of patients with PD systematically sampled by age at onset have not been reported to date...
  10. pmc Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease
    Roy N Alcalay
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Clin Exp Neuropsychol 32:775-9. 2010
    ..GBA carriers reported more impairment, but MMSE performance did not differ among genetic groups. Detailed neuropsychological testing is required to explore the association between cognitive impairment and GBA mutations...
  11. pmc Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study
    Roy N Alcalay
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Arch Neurol 67:1116-22. 2010
    ..To assess the frequency and clinical characteristics of carriers of previously identified mutations in 6 genes associated with early-onset Parkinson disease (PD) and provide empirical data that can be used to inform genetic counseling...
  12. ncbi Case-control study of the parkin gene in early-onset Parkinson disease
    Lorraine N Clark
    Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Arch Neurol 63:548-52. 2006
    ..To our knowledge, all previous studies have been restricted to PD cases; this is the first study to systematically screen the parkin coding regions and exon deletions and duplications in controls...
  13. pmc Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population
    Xinmin Liu
    Taub Institute for Research on Alzheimer s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    BMC Med Genet 12:104. 2011
    ..Collectively the associations identified in these GWAS account for only a small proportion of the estimated total heritability of PD suggesting that an 'unknown' component of the genetic architecture of PD remains to be identified...
  14. pmc Association of glucocerebrosidase mutations with dementia with lewy bodies
    Lorraine N Clark
    Taub Institute for Research onAlzheimer s Disease and the Aging Brain, Columbia University, New York, NY 10032, USA
    Arch Neurol 66:578-83. 2009
    ..Mutations in the glucocerebrosidase (GBA) gene are associated with Lewy body (LB) disorders...
  15. ncbi Contribution of aging to the severity of different motor signs in Parkinson disease
    Gilberto Levy
    Statistical Analysis Center, Department of Biostatistics, Columbia University, New York, NY 10032, USA
    Arch Neurol 62:467-72. 2005
    ..This knowledge may have implications for clinical trials of neuroprotective agents in PD...
  16. ncbi A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations
    Karen Blindauer
    Department of Neurology, Medical College of Wisconsin, Milwaukee 53226, USA
    Arch Neurol 63:210-6. 2006
    ..Etilevodopa is an ethyl-ester prodrug of levodopa that has greater gastric solubility, passes quickly into the small intestine, is rapidly hydrolyzed to levodopa, and has a shortened time to maximum levodopa concentration...
  17. doi Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
    ..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
  18. pmc Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease
    Roy N Alcalay
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Arch Neurol 66:1517-22. 2009
    ....
  19. pmc Clinical and pathological characteristics of LRRK2 G2019S patients with PD
    Markos Poulopoulos
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    J Mol Neurosci 47:139-43. 2012
    ..However, the extent of cortical involvement is variable. Larger longitudinal follow-up of LRRK2 G2019S mutation carriers is required to assess for risk factors for cortical involvement and dementia...
  20. ncbi Rasagiline improves quality of life in patients with early Parkinson's disease
    Kevin M Biglan
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Mov Disord 21:616-23. 2006
    ..Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline...
  21. ncbi Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  22. ncbi Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
    J Antonelle deMarcaida
    Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
    Mov Disord 21:1716-21. 2006
    ..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction...
  23. ncbi Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene
    Lorraine N Clark
    Department of Pathology, Columbia University, New York, New York 10032, USA
    Mov Disord 22:932-7. 2007
    ..Here, we show the utility of a genotyping array for Parkinson's disease by analysis of 60 subjects from the Genetic Epidemiology of Parkinson Disease (GEPD) study that includes 15 early-onset PD case probands and 45 relatives...
  24. doi Cognitive and Motor Function in Long-Duration PARKIN-Associated Parkinson Disease
    Roy N Alcalay
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York2Taub Institute for Research on Alzheimer s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York
    JAMA Neurol 71:62-7. 2014
    ..A longitudinal follow-up study is required to confirm these findings. ..
  25. pmc Fatigue in levodopa-naive subjects with Parkinson disease
    G Schifitto
    University of Rochester, NY, USA
    Neurology 71:481-5. 2008
    ..Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated patients with early PD enrolled in the Earlier vs Later Levodopa (ELLDOPA) clinical trial...
  26. pmc Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants
    K Marder
    Departments of Neurology and Psychiatry, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Gertrude H Sergievsky Center, Columbia University, New York, NY 10032, USA
    Neurology 73:385-92. 2009
    ..To examine caloric intake, dietary composition, and body mass index (BMI) in participants in the Prospective Huntington At Risk Observational Study (PHAROS)...
  27. doi A study of chorea after tetrabenazine withdrawal in patients with Huntington disease
    Samuel Frank
    Department of Neurology, Boston University School of Medicine, Boston, MA, USA
    Clin Neuropharmacol 31:127-33. 2008
    ..To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal...
  28. ncbi Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity
    Lorraine N Clark
    Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Columbia University, New York, New York, USA
    Mov Disord 20:100-3. 2005
    ..2). A total of 17 PD cases carry the N370S allele, including 2 homozygotes and 15 heterozygotes. The N370S allele (nt.1226 A>G) may be associated with PD in patients of Jewish ethnicity and should be examined in a larger study...
  29. doi Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis
    Chris C Tang
    Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, NY, USA
    Lancet Neurol 9:149-58. 2010
    ..We aimed to assess whether metabolic brain imaging combined with spatial covariance analysis could accurately discriminate patients with parkinsonism who had different underlying disorders...
  30. ncbi Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation
    Melissa J Nirenberg
    Division of Movement Disorders, Department of Neurology, Weill Cornell Medical College, New York, New York 10021, USA
    Mov Disord 22:251-4. 2007
    ..These findings suggest that abnormal expansion of the SCA3 gene may be a risk factor for the development of MSA-C...
  31. ncbi ALS lessons learned from other neurological diseases. Parkinson's disease
    Stanley Fahn
    Columbia University, New York, New York, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:26-30. 2004
  32. ncbi Status of fetal tissue transplantation for the treatment of advanced Parkinson disease
    Paul E Greene
    Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Neurosurg Focus 13:e3. 2002
    ..The authors believe that these problems must be solved before fetal tissue transplantation can be considered a therapeutic option for PD...
  33. doi A longitudinal program for biomarker development in Parkinson's disease: a feasibility study
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 24:2081-90. 2009
    ..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data...
  34. ncbi Familial aggregation of early- and late-onset Parkinson's disease
    Karen Marder
    Department of Neurology, Columbia University, New York, NY, USA
    Ann Neurol 54:507-13. 2003
    ..Genetic factors are important in both early- and late-onset PD, but specific genes and mode of inheritance may differ between the two groups...
  35. ncbi Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations
    Lorraine N Clark
    Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Columbia University, New York, New York, USA
    Mov Disord 19:796-800. 2004
    ..Mutations in the DJ-1 gene are rare in EOPD in both sporadic and familial cases...
  36. ncbi Diagnosing Parkinson's disease using videotaped neurological examinations: validity and factors that contribute to incorrect diagnoses
    Elan D Louis
    The Gertrude H Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Mov Disord 17:513-7. 2002
    ..A limitation is that patients with milder PD of shorter duration may not be recognized as PD...
  37. ncbi Woman with a 26-year history of parkinsonism, supranuclear ophthalmoplegia, and loss of postural reflexes
    Paul H Gordon
    Department of Neurology, Division of Movement Disorders, Columbia Presbyterian Medical Center, New York, New York 10032, USA
    Mov Disord 19:950-61. 2004
    ..A woman who had her first serious fall at age 48 years subsequently developed neurological symptoms. Her case is described, differential diagnoses are presented, pathology is discussed, and a final diagnosis is reached...
  38. ncbi Reaction time and movement time after embryonic cell implantation in Parkinson disease
    Paul H Gordon
    Department of Neurology and Clinical Motor Physiology Laboratory, Columbia Presbyterian Medical Center, New York, NY 10032, USA
    Arch Neurol 61:858-61. 2004
    ..Reaction time (RT) and movement time (MT) analysis, validated quantitative measures of premovement neural processing and motor execution, can be used as objective physiological markers of motor performance in PD...
  39. doi Parkinson's disease: 10 years of progress, 1997-2007
    Stanley Fahn
    Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Mov Disord 25:S2-14. 2010
    ....
  40. ncbi Treatment issues in psychogenic-neuropsychiatric movement disorders
    Daniel T Williams
    Department of Psychiatry, Columbia University, New York, New York, USA
    Adv Neurol 96:350-63. 2005
    ....
  41. ncbi Movement disorders fellowship training program at Columbia University Medical Center in 2001-2002
    Carlos Portera-Cailliau
    Department of Neurology, Columbia University Medical Center, New York, New York, USA
    Mov Disord 21:479-85. 2006
    ..Video rounds allow greater exposure to uncommon diagnoses. Similar data from other movement disorder training programs are needed to help create guidelines for formal accreditation and to improve clinical training in this subspecialty...
  42. pmc Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations
    Roy N Alcalay
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA Taub Institute for Research on Alzheimer s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Mov Disord 28:1966-71. 2013
    ..2013 International Parkinson and Movement Disorder Society. ..
  43. doi Botulinum toxin for the treatment of movement disorders
    Mary Ann Thenganatt
    Department of Neurology, College of Physicians and Surgeons, Columbia University, 710 West 168th Street, New York, NY 10032, USA
    Curr Neurol Neurosci Rep 12:399-409. 2012
    ..We review the history and mechanism of action of botulinum toxin, as well as describe different formulations available and their potential therapeutic uses in movement disorders...
  44. ncbi Diagnosis and management of pergolide-induced fibrosis
    Pinky Agarwal
    Department of Neurology, Columbia Presbyterian Medical Center, Division of Movement Disorders, New York, New York, USA
    Mov Disord 19:699-704. 2004
    ..Based on our experience with these patients and a review of cases of pergolide-induced fibrosis in the English-language literature, we propose guidelines for the diagnosis and management of this rare complication...
  45. doi Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes
    Rebecca M Wolf Gilbert
    Department of Neurology, NYU Langone Medical Center, New York, New York 10016, USA
    Mov Disord 25:1868-75. 2010
    ..Having MND may be a risk factor for parkinsonism. A prospective study may elucidate this possibility...
  46. ncbi Lack of familial aggregation of Parkinson disease and Alzheimer disease
    Gilberto Levy
    Statistical Analysis Center, Department of Biostatistics, Columbia University, 630 W 168th Street, New York, NY 10032, USA
    Arch Neurol 61:1033-9. 2004
    ..To investigate the risk of Alzheimer disease (AD) in first-degree relatives of patients with Parkinson disease (PD) compared with first-degree relatives of controls...
  47. doi Classification of movement disorders
    Stanley Fahn
    Department of Neurology, Columbia University Medical Center, New York, New York, USA
    Mov Disord 26:947-57. 2011
    ..First is a review of movement disorders as a group; then, the evolving classifications for 3 of them--parkinsonism, dystonia, and tremor--are covered in detail...
  48. ncbi Severe cervical dystonia in pathologically proven Parkinson's disease and dementia
    Oren Cohen
    Department of Neurology, Columbia Presbyterian Medical Center, New York, New York, USA
    Mov Disord 18:1381-2. 2003
    ..The clinical diagnosis of Parkinson's disease and dementia (PDD) was confirmed at autopsy...
  49. ncbi The early history of paroxysmal dyskinesias
    Stanley Fahn
    Department of Neurology, Columbia University, Columbia Presbyterian Medical Center, Neurological Institute, New York, New York, USA
    Adv Neurol 89:377-85. 2002
  50. ncbi The Unified Myoclonus Rating Scale
    Steven J Frucht
    Department of Neurology, Columbia University, Columbia Presbyterian Medical Center, Neurological Institute, New York, New York, USA
    Adv Neurol 89:361-76. 2002
  51. ncbi Overview, history, and classification of myoclonus
    Stanley Fahn
    Department of Neurology, Columbia University, Columbia Presbyterian Medical Center, Neurological Institute, New York, New York, USA
    Adv Neurol 89:13-7. 2002
  52. ncbi Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    Ira Shoulson
    University of Rochester Medical Center, Rochester, NY 14620, USA
    Ann Neurol 51:604-12. 2002
    ....
  53. ncbi Does personality change as a result of fetal tissue transplantation in the brain?
    Cynthia McRae
    College of Education, University of Denver, Denver, CO 80208, USA
    J Neurol 250:282-6. 2003
    ..Results indicate that personality, as measured by the NEO-FFI, basically remained stable during the two-year follow-up period of this study. In this case, no change is regarded as a positive outcome...
  54. ncbi Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism
    Norman Kock
    Ann Neurol 52:257-8; author reply 258. 2002
  55. ncbi Dyskinesia after fetal cell transplantation for parkinsonism: a PET study
    Yilong Ma
    Center for Neurosciences, North Shore Long Island Jewish Research Institute and Department of Neurology, North Shore University Hospital, 350 Community Drive, Manhasset, NY 11030, USA
    Ann Neurol 52:628-34. 2002
    ..These findings suggest that unbalanced increases in dopaminergic function can complicate the outcome of neuronal transplantation for parkinsonism...
  56. ncbi Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan
    Christopher G Goetz
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 22:41-7. 2007
    ....
  57. ncbi Preoperative response to levodopa is the best predictor of transplant outcome
    Curt R Freed
    Ann Neurol 55:896; author reply 896-7. 2004
  58. doi Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Connecticut 06030 3940, USA
    Hypertension 52:587-93. 2008
    ..3%, 2.6%, and 2.9% of the placebo, 0.5-mg, and 1.0-mg rasagiline groups, respectively. These data demonstrate that rasagiline did not induce postprandial hypertension in patients with Parkinson disease who were on an unrestricted diet...
  59. ncbi Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial
    Cynthia McRae
    College of Education, University of Denver, Denver, CO 80208, USA
    Arch Gen Psychiatry 61:412-20. 2004
    ..This portion of the study investigated the quality of life (QOL) of participants during the 1 year of double-blind follow-up...
  60. pmc Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
    ..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
  61. doi Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions
    Christopher G Goetz
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 23:690-9. 2008
    ..Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials...
  62. ncbi Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial
    Connie Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 23:653-9; quiz 776. 2008
    ..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL...
  63. ncbi Huntington's Disease-like 2 (HDL2) in North America and Japan
    Russell L Margolis
    Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Ann Neurol 56:670-4. 2004
    ..0098). The results further support the evidence that the repeat expansion at the chromosome 16q24.3 locus is the direct cause of HDL2 and provide preliminary guidelines for the genetic testing of patients with an HD-like phenotype...
  64. ncbi Deep-brain stimulation extends relief from Parkinson's. Electrodes deep in the brain continue relieving Parkinson's disease symptoms for five years
    Stanley Fahn
    Health News 10:6-7. 2004
  65. ncbi Benefits and risks of pharmacological treatments for essential tremor
    Kelly E Lyons
    University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Drug Saf 26:461-81. 2003
    ..The use of medication and/or surgery can provide adequate tremor control in the majority of the patients...
  66. ncbi Methylphenidate treats apathy in Parkinson's disease
    Anjan Chatterjee
    J Neuropsychiatry Clin Neurosci 14:461-2. 2002
  67. ncbi Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency
    Yoshiaki Furukawa
    Ann Neurol 55:147-8. 2004